Product Description for Cibinqo (Abrocitinib)

Cibinqo, also known as Abrocitinib, is a targeted oral medication designed for the treatment of moderate to severe atopic dermatitis in adults and pediatric patients aged 12 years and older. This innovative therapy works by inhibiting specific enzymes involved in the inflammatory process, helping to reduce the symptoms associated with atopic dermatitis.

How Cibinqo Works

Cibinqo selectively inhibits Janus kinase (JAK) pathways, which play a crucial role in the inflammatory response. By blocking these pathways, Cibinqo helps to alleviate itching, redness, and inflammation, leading to improved skin condition and quality of life for patients.

Indications

Cibinqo is indicated for the treatment of:

• Moderate to severe atopic dermatitis in adults and adolescents (12 years and older) who are candidates for systemic therapy.

Dosage and Administration

The recommended dosage of Cibinqo is determined by the healthcare provider based on the patient's condition and response to treatment. It is important to follow the prescribed dosage and schedule.

Common Side Effects

Patients may experience side effects, including:

• Headache
• Nausea
• Fatigue
• Upper respiratory infections

It is essential to consult with a healthcare professional for a complete list of potential side effects and any concerns regarding the use of Cibinqo.

Precautions

Prior to starting treatment with Cibinqo, patients should inform their healthcare provider about any underlying health conditions, medications they are currently taking, and any history of infections or cancers.

Conclusion

Cibinqo (Abrocitinib) represents a significant advancement in the management of atopic dermatitis, offering a targeted approach to reduce symptoms and improve the quality of life for patients. Always consult with a healthcare professional for personalized medical advice and treatment options.